We recently compiled a list of the 10 Best US Stocks to Buy Under $10. In this article, we are going to take a look at where Teladoc Health Inc. (NYSE:TDOC) stands against the other US stocks.
Value in Small-Caps
As the market continues progressing, there is a cautiously optimistic sentiment surrounding small-cap stocks. While many investors are comfortable with economic fundamentals, concerns about high valuations persist. Although the overall market may seem expensive, this is primarily due to the largest market-cap stocks, leaving room for growth in smaller companies.
As global markets improve amid a broader easing cycle, these stocks could play an essential role in portfolio diversification. The focus should be on identifying value beyond mega-cap stocks to uncover opportunities in various sectors and regions. This strategic positioning was highlighted by Sebastien Page of T. Rowe Price on CNBC just a few days ago. We covered his opinions regarding small caps in our article on the 10 Most Promising Penny Stocks According to Hedge Funds. Here’s an excerpt from that:
“Page highlighted that their current strategy includes a slight overweight of half a percent in stocks compared to bonds, which marks an increase in risk appetite compared to previous conversations over the last 18 months. He acknowledged that while the overall market multiple may appear expensive, it is skewed by the largest market-cap stocks. This suggests that there are still opportunities beyond mega-cap names, which have become too consensus-driven and costly.
Addressing concerns about valuations, Page pointed out that while the price-to-earnings ratio appears high, it is essential to consider the context. He mentioned that if one adjusts for return on equity, current valuations may fall below historical medians. Additionally, he noted that the average stock globally trades at a P/E of about 13, which aligns with its long-term average. This indicates that while some segments may seem overvalued, many stocks are positioned reasonably relative to their historical performance.”
On October 11, CNBC’s Mike Santoli and Northwestern Mutuals’ Brent Schutte, joined ‘Power Lunch’ on CNBC to discuss the CPI report numbers and the market reaction. Brent Schutte believes that small and mid-cap stocks offer value regardless of the Fed’s landing.
He expressed concerns about the potential for a wage-price spiral, particularly in light of significant wage increases expected for major employers. He highlighted that these wage hikes could contribute to continued inflation, especially as the economy is already in a late-cycle with fewer available workers. Although unemployment has slightly increased, he emphasized that if demand picks up, it would be challenging to keep inflation in check. He pointed out that rising wages represent a critical factor for the Fed as it navigates monetary policy.
Schutte noted that historically, the Fed has struggled with balancing inflation and employment signals, often reacting too late to emerging trends. He indicated that while there are signs of weakening in the labor market, the current inflationary pressures are still significant. He referred to recent data showing that median CPI rose by 0.4%, which suggests that the path forward may be more complicated than investors currently anticipate.
Mike Santoli added to the conversation by discussing what will dominate market focus in the coming weeks. He mentioned earnings reports as a key factor, alongside economic data and potential impacts from the upcoming elections, acknowledging that while stickier inflation could eventually pose challenges for the Fed, he doesn’t believe this will happen immediately given current interest rates between 4.57% and 5%. He suggested that the stock market might not react negatively to less Fed accommodation if it coincides with a stronger economy.
Discussing large-cap stocks and their performance in this late-cycle phase of the economy, Santoli expressed concern about whether small-cap stocks would eventually take over as leaders in the market. He drew parallels to past market conditions where narrow leadership was evident during economic slowdowns. He noted that small and mid-cap stocks have been priced for recession, and their performance on days when rates rise indicates they are under pressure compared to larger stocks.
Schutte then talked about the implications of persistent inflation on small-cap earnings, highlighting that Russell 2000 earnings had been flat for 3 years amid rising rates. He questioned how much of this scenario is already priced into the market and pointed out that many investors have gravitated towards mega-cap stocks due to their perceived stability amidst economic uncertainty.
Schutte emphasized the importance of monitoring economic indicators to make decisions on small-caps among other stocks, but to ease up the search for you, we’re here with a list of the 10 best US stocks to buy under $10.
Methodology
We used the Finviz screener to compile a list of 30 large US stocks that were trading below $10. We then selected the 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q2 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 900 elite money managers.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A doctor wearing a face mask and lab coat providing remote medical advice via video chat.
Teladoc Health Inc. (NYSE:TDOC)
Share Price as of October 16: $9.51
Number of Hedge Fund Holders: 35
Teladoc Health Inc. (NYSE:TDOC) is a telemedicine and virtual healthcare company headquartered in the US that provides services like telehealth, medical opinions, AI and analytics, telehealth devices, and licensable platform services. Patients can consult with doctors, therapists, and other healthcare professionals via video or phone calls, without the need for in-person appointments.
In the second quarter of 2024, it made $642.44 million in revenue, recording a decline of 1.53% compared to a year-ago period, as average paid users declined by 1.9% sequentially. BetterHelp segment, revenue was down 9%. The decline in revenue and users was a result of fewer user additions to the platform.
The majority of the drop was offset by strong segment results. Integrated Care segment revenue increased 5% year-over-year to $377 million. Chronic Care was a key contributor to this growth. The company ended the quarter with Chronic Care Program Enrollment of $1.17 million, up 9% year-over-year, and up 5% sequentially. The largest drivers of Chronic Care Enrollment growth were the Diabetes Prevention & Weight Management programs, followed by Hypertension. International revenue growth was driven by the B2B business mainly.
Teladoc Health Inc. (NYSE:TDOC) is strategically investing in AI and partnering with tech giants to enhance its virtual care platform. In recent months, the company has collaborated with Microsoft to integrate ambient clinical documentation and OpenAI services into its Solo platform. Additionally, it has been developing its own AI models to improve patient-provider matching and other key functions.
Its integration of AI is poised to drive sustained growth and solidify its position as a leader in virtual healthcare. As AI technology continues to evolve, this company is well-positioned to capitalize on emerging opportunities.
Brown Capital Management Mid Company Fund stated the following regarding Teladoc Health, Inc. (NYSE:TDOC) in its Q2 2024 investor letter:
“Teladoc Health, Inc. (NYSE:TDOC) operates a telehealth platform that provides on-demand healthcare services to its members in the U.S. and abroad. Its solution connects consumers with physicians and behavioral health professionals who treat a range of conditions. The company offers its services through mobile devices, desktop, and by video or phone. Our initial excitement over Teladoc’s market-leading position, large market opportunity and compelling value proposition ran into the reality of the company’s deteriorating fundamentals. Competitive pressure, high customer-acquisition costs and poor customer retention significantly impaired the company since our initial purchase in March 2020. Additionally, questionable acquisitions and executive turnover further weighed on the business, resulting in revenue growth declining from the high-20s/low-30s to low-single-digits without any improvement in profitability. Although we pride ourselves on being patient and tolerant, it became obvious that our investment thesis was wrong, and we sold the company from the Fund.”
Overall TDOC ranks 10th on our list of the best US stocks to buy under $10. While we acknowledge the growth potential of TDOC as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TDOC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
